Granted Patent
B2
US 12,540,327 · App. 18/932,368 · Granted Feb 3, 2026
Composition for regulating production of interfering ribonucleic acid
Assignee:
Wyvern Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a kinase.
Claims (4)
1 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO: 9.
2 . The composition of claim 1 , wherein the RP is encased encapsulated in a protein coat, a lipid vesicle, or any combination thereof.
3 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO: 17.
4 . The composition of claim 3 , wherein the RP is encapsulated in a protein coat, a lipid vesicle, or any combination thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 20, 2025
From: THOPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 072073/0434 →
Continuity (2)
References Cited (37)
CA 2721333A1
· 2009
[cited by applicant]
Fiona T van den Berg, et al., Molecular Therapy—Nucleic Acids, vol. 5, 2016 (Year: 2016).
[cited by examiner]
Denzler R et al., Mol Cell. Nov. 3, 2016;64(3):565-579 (Year: 2016).
[cited by examiner]
O'Brien, et al., Aug. 3, 2018, Front Endocrinol (Lausanne), 9:402, p. 1-12; Fig. 1; p. 2, “Biogenesis of miRNAs” (Year: 2018).
[cited by examiner]
Gorski, S., Vogel, J. & Doudna, J., Nat Rev Mol Cell Biol 18, 215-228 (2017) (Year: 2017).
[cited by examiner]
Nature (2010. Gene Expression. Scitable. Available online at Nature.com. Accessed Dec. 16, 2024) (Year: 2010).
[cited by examiner]
NCBI Nucleotide Sequence for PARP. Search performed Dec. 26, 2024 (Year: 2024).
[cited by examiner]
Tritschler (et al. 2019. Concepts and limitations for learning developmental trajectories from single cell genomics. Development 146: dev170506) (Year: 2019).
[cited by examiner]
Bottoni et al. “Targeting BTK through microRNA in chronic lymphocytic leukemia.” Blood, The Journal of the American Society of Hematology 128.26 (2016): 3101-3112.
[cited by applicant]
Brutons Tyrosine Kinase Genbank Sequence (Year: 2023).
[cited by applicant]
Christensen et al. “Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo.” Frontiers in neural circuits 3 (2010): 848.
[cited by applicant]
Bofill-De Ros et al. “Guidelines for the optimal design of miRNA-based shRNAs.” Methods 103 (2016): 157-166.
[cited by applicant]
NCBI Nucleotide Sequence ALK Lingand, search performed Dec. 26, 2024 (2023).
[cited by applicant]
Ahmadzadeh et al. “BRAF mutation in hairy cell leukemia.” Oncology reviews 8.2 (2014): 253.
[cited by applicant]
Patton et al. “Biogenesis, delivery, and function of extracellular RNA.” Journal of extracellular vesicles 4.1 (2015): 27494.
[cited by applicant]
Clark et al. “Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies.” Oncotarget 11.44 (2020): 4016.
[cited by applicant]
NCBI Search results for SEQ ID No. 5 2024.
[cited by applicant]
GenBank EGFR Sequence (2023).
[cited by applicant]
Genbank FLT3 Sequence (2024).
[cited by applicant]
Lam (et al. 2015. siRNA Versus miRNA as Therapeutics for Gene Silencing. Molec. Ther. Nuc. Ac. 4:e252) (Year: 2015).
[cited by applicant]
Ying (et al. 2008. The MicroRNA (miRNA): Overview of the RNA Genes that Modulate Gene Function. Mol. Biotechnol. 38:257-268) (Year: 2008).
[cited by applicant]
[cited by applicant]
Pagliuca (et al. 2013. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene 32:4806-4813) (Year: 2013.
[cited by applicant]
Fattore (et al. 2016. miR-579-3p controls melanoma progression and resistance to target therapy. PNAS 113 [34]:E5005-E5013) ( Year: 2016).
[cited by applicant]
Origene (2024. Product datasheet for SC207797 B Raf [BRAF] [NM_004333] Human 3′ UTR Clone. Rockville, MD: Origene) (Year: 2024).
[cited by applicant]
NCBI (
[cited by applicant]
MiRbase (2025. “miR-143” and “miR-145”, and “miR-579-3p”. Available online at miRbase.org. Accessed on May 16, 2025) (Year: 2025).
[cited by applicant]
Kondratov et al. “Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells.” Molecular Therapy 25.12 (2017): 2661-2675.
[cited by applicant]
Wang et al. “Adeno-associated virus vector as a platform for gene therapy delivery”. Nat Rev Drug Discov. May 2019; 18(5):358-378. (Year: 2019).
[cited by applicant]
NCBI Nucleotide Sequence ALK Receptor, search performed Dec. 26, 2024 (2023).
[cited by applicant]
Gen Bank EGF Sequence (2023).
[cited by applicant]